← All trials
NCT05633147
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 27, 2022
- Primary completion
- Jan 27, 2023
- Completion date
- Feb 3, 2023
- First posted
- Dec 1, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cinclus Pharma AGLead sponsor
- Clinical Trial Consultants ABStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.